Newsroom
Top Results
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study […]
Sight Sciences Announces the Closing of its $7MM Series B Financing Led by Hicks Equity Partners
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed a $7 million Series B round of financing. The round was led by Hicks Equity Partners, a leading private equity firm based in Dallas, Texas. All Series A investors participated in the oversubscribed Series B round, including Scientific Health […]
Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales […]
Sight Sciences Secures $10MM in Oversubscribed Series C Financing
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with a seasoned ophthalmic industry veteran. Allegro Investment Fund, a privately held fund based in Menlo Park, CA, led the round with full participation from all existing […]
Sight Sciences Names Jesse Selnick Chief Financial Officer
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the appointment of Jesse Selnick as Chief Financial Officer. Selnick most recently served as Chief Financial Officer and on the Board of Directors of Electric Lightwave, a private equity sponsored […]
Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has joined the company as Chief Medical Officer (CMO). Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma. […]
Sight Sciences Hires Leading Industry Executives to Drive Continued Growth
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan and Jim Sluck have joined the company as Vice President of Health Policy & Reimbursement, Vice President of Strategy & Professional Relations and Vice President […]
Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million in Series D Preferred Stock financing led by KCK Group, a leading investor in high growth medical technology companies. MidCap Financial, a prominent middle-market lender […]